| New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape D Mittal, MM Gubin, RD Schreiber, MJ Smyth Current opinion in immunology 27, 16-25, 2014 | 1915 | 2014 |
| Targeting cancer-derived adenosine: new therapeutic approaches A Young, D Mittal, J Stagg, MJ Smyth Cancer discovery 4 (8), 879-888, 2014 | 327 | 2014 |
| Targeted therapies for triple-negative breast cancer: combating a stubborn disease M Kalimutho, K Parsons, D Mittal, JA López, S Srihari, KK Khanna Trends in pharmacological sciences 36 (12), 822-846, 2015 | 320 | 2015 |
| Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor D Mittal, A Young, K Stannard, M Yong, MWL Teng, B Allard, J Stagg, ... Cancer research 74 (14), 3652-3658, 2014 | 281 | 2014 |
| Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy SMJ Blake S, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Roman Aguilera A ... Cancer Discovery, 2016 | 237 | 2016 |
| TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells D Mittal, F Saccheri, E Vénéreau, T Pusterla, ME Bianchi, M Rescigno The EMBO journal 29 (13), 2242-2252, 2010 | 202 | 2010 |
| Adenosine 2B receptor expression on cancer cells promotes metastasis D Mittal, D Sinha, D Barkauskas, A Young, M Kalimutho, K Stannard, ... Cancer research 76 (15), 4372-4382, 2016 | 172 | 2016 |
| Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis D Mittal, D Vijayan, EM Putz, AR Aguilera, KA Markey, J Straube, ... Cancer immunology research 5 (12), 1098-1108, 2017 | 132 | 2017 |
| CD73 promotes resistance to HER2/ErbB2 antibody therapy M Turcotte, D Allard, D Mittal, Y Bareche, L Buisseret, V José, S Pommey, ... Cancer research 77 (20), 5652-5663, 2017 | 109 | 2017 |
| CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function D Mittal, A Lepletier, J Madore, AR Aguilera, K Stannard, SJ Blake, ... Cancer immunology research 7 (4), 559-571, 2019 | 102 | 2019 |
| NK cells require IL-28R for optimal in vivo activity F Souza-Fonseca-Guimaraes, A Young, D Mittal, L Martinet, C Bruedigam, ... Proceedings of the National Academy of Sciences 112 (18), E2376-E2384, 2015 | 96 | 2015 |
| CEP 55 is a determinant of cell fate during perturbed mitosis in breast cancer M Kalimutho, D Sinha, J Jeffery, K Nones, S Srihari, WC Fernando, ... EMBO molecular medicine 10 (9), e8566, 2018 | 75 | 2018 |
| Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer PV Raninga, AC Lee, D Sinha, YY Shih, D Mittal, A Makhale, AL Bain, ... International journal of cancer 146 (1), 123-136, 2020 | 72 | 2020 |
| Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov. 2014; 4: 879–888. doi: 10.1158/2159-8290 A Young, D Mittal, J Stagg, MJ Smyth CD-14-0341.[Abstract][CrossRef][Google Scholar], 0 | 68 | |
| New approaches to immunotherapy for HPV associated cancers AS Bergot, A Kassianos, IH Frazer, D Mittal Cancers 3 (3), 3461-3495, 2011 | 64 | 2011 |
| Indoleamine 2, 3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7 D Mittal, AJ Kassianos, LS Tran, AS Bergot, C Gosmann, J Hofmann, ... Journal of Investigative Dermatology 133 (12), 2686-2694, 2013 | 62 | 2013 |
| Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice J Overman, F Fontaine, M Moustaqil, D Mittal, E Sierecki, N Sacilotto, ... Elife 6, e21221, 2017 | 57 | 2017 |
| Intra‐tumoral Salmonella typhimurium induces a systemic anti‐tumor immune response that is directed by low‐dose radiation to treat distal disease F Avogadri, D Mittal, F Saccheri, M Sarrafiore, M Ciocca, P Larghi, ... European journal of immunology 38 (7), 1937-1947, 2008 | 55 | 2008 |
| CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity A Roman Aguilera, VP Lutzky, D Mittal, XY Li, K Stannard, K Takeda, ... Oncoimmunology 7 (5), e1424677, 2018 | 50 | 2018 |
| Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis H Harjunpää, SJ Blake, E Ahern, S Allen, J Liu, J Yan, V Lutzky, K Takeda, ... Oncoimmunology 7 (7), e1445949, 2018 | 47 | 2018 |
